Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Cent Eur J Immunol ; 44(2): 132-137, 2019.
Article in English | MEDLINE | ID: mdl-31530982

ABSTRACT

AIM OF THE STUDY: Assessment of the peripheral blood picture and aminotransferase activity in children with newly diagnosed Graves' disease (GD) at baseline and 4-6 weeks after the initiation of antithyroid drug (ATD) therapy. MATERIAL AND METHODS: Data of 59 children were assessed retrospectively. Baseline analysis included concentrations of thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), TSH receptor antibodies (TSH-R Ab), complete blood cell count (CBC), aspartate (AST) and alanine aminotransferase (ALT) activity. Reassessment of CBC and aminotransferase activity was performed 4-6 weeks after the initiation of ATD therapy. RESULTS: Significant decreases in the neutrophil count, MCV, haemoglobin (Hgb), red blood cell (RBC) count, white blood cell (WBC) count and platelet (PLT) count were found in 37.3%, 32.2%, 22%, 13.6%, 8.5% and 5% of untreated patients, respectively. Increased baseline ALT and AST activity was observed in 44% and 32.2% of children, respectively. Initiation of ATD therapy led to significant changes in Hgb, RBC and PLT count, RDW and ALT activity. Negative associations between TSH-R Ab, TSH and MCV were found. ALT and AST activity were negatively related to baseline TSH levels. ALT activity was also associated with baseline fT4 and fT3. CONCLUSIONS: The incidence of haematopoiesis and liver abnormalities in GD children seems to be similar to that reported in adult patients. The most common alterations are changes in neutrophil count, RBC parameters and ALT activity. The initiation of ATD therapy usually leads to significant improvement in those parameters.

2.
Cent Eur J Immunol ; 43(3): 255-261, 2018.
Article in English | MEDLINE | ID: mdl-30588169

ABSTRACT

AIM OF THE STUDY: The aim of this study was to investigate the effects of growth hormone (GH) therapy on thyroid function in a group of euthyroid children with isolated idiopathic growth hormone deficiency (GHD). MATERIAL AND METHODS: The study was retrospective and included 117 children treated with GH for 1-4 years. Anthropometric measurements and serum concentrations of insulin-like growth factor-1 (IGF-1), thyroid-stimulating hormone (TSH), and free thyroxine (fT4) were analysed at baseline and during GH therapy. RESULTS: TSH levels did not change significantly after the initiation of GH treatment, while fT4 levels decreased after the second year of GH treatment (p < 0.01) and remained lower than baseline until the end of observation (p < 0.01, after both the third and fourth year of therapy) in the whole group. Analysis according to baseline pubertal status revealed significant changes in TSH and fT4 levels during GH treatment, but only in the prepubertal children. Multiple regression analysis confirmed that mean GH doses administered in the first two years of GH therapy were independently (R = 0.218, p < 0.05) associated with changes in fT4 levels in this period (∆fT42 years - baseline), even when taking into account changes in height SDS and bone age. CONCLUSIONS: FT4 levels decreased during GH replacement therapy, while TSH levels appeared to be unaffected by GH therapy. Prepubertal children seem to be more predisposed to thyroid function alterations during such therapy in comparison to pubertal children. Changes in fT4 levels during GH replacement therapy are related to GH doses.

3.
Cent Eur J Immunol ; 43(4): 399-404, 2018.
Article in English | MEDLINE | ID: mdl-30799987

ABSTRACT

Grave's disease (GD) is a form of thyroid autoimmune disease characterised by hyperthyroidism. It is a rare clinical problem in paediatrics. Development of disease is the result of genetic susceptibility and some environmental factors. One of the best-documented environmental factors involved in thyroid autoimmunity is iodine excess. The aim of our study was to analyse the clinical course and response to pharmacological treatment in children diagnosed with Graves' disease in first two decades after mandatory salt iodination. Records of 94 children diagnosed with GD in the years 1998-2017 were analysed. Medical data of patients was compared between two decades following implementation of iodine prophylaxis: 1998-2007 (first-decade group - FDG) and 2008-2017 (second-decade group - SDG); 34 and 60 patients, respectively. Medical data of FDG was obtained from archival records and previous analysis performed in 2006. Data of 60 patients from SDG were obtained from currently available medical records. Results were statistically analysed using Microsoft Excel and Statistica 11 software. Results: In our study, after mandatory salt iodination, the tendency of an increase in newly diagnosed GD in children without family susceptibility was observed. The antibody profile indicates the significant contribution of the autoimmune process involving all thyroid antigens; therefore, the term "autoimmune hyperthyroidism" seems to be more appropriate than classical GD in this group of patients. The first-choice treatment with methimazole rarely causes adverse events during the therapy, and they have benign character.

4.
Adv Exp Med Biol ; 1022: 71-76, 2017.
Article in English | MEDLINE | ID: mdl-28456931

ABSTRACT

Turner syndrome is associated with increased incidence of autoimmune diseases, especially those of the thyroid gland. The aim of this study was to assess the prevalence of thyroid autoimmunity among pediatric patients with Turner syndrome. The study was retrospective and included 41 girls with Turner syndrome aged 6-18 years. Free thyroxine (FT4), thyroid stimulating hormone (TSH), anti-thyroid peroxidase (TPO-Ab) antibodies, anti-thyroglobulin (TG-Ab) antibodies, and karyotype were investigated. The correlation between karyotype and incidence of thyroid autoimmunity was also examined. Eleven patients (26.8%) were positive for TPO-Ab and/or TG-Ab. Three girls from that subgroup were euthyroid, 5 had subclinical hypothyroidism, and 3 were diagnosed with overt hypothyroidism. Out of these 11 patients affected by thyroid autoimmunity, 6 girls had mosaic karyotype with X-isochromosome (n = 4) or with deletions (n = 2), and 5 had the 45,X karyotype. The study findings confirmed a high incidence of thyroid autoimmunity in girls with Turner syndrome, but we failed to observe an association between the incidence of thyroid autoimmunity and karyotype. We conclude that it is important to monitor thyroid function in patients with Turner syndrome because they are prone to develop hypothyroidism.


Subject(s)
Autoantibodies/blood , Autoimmunity/physiology , Hypothyroidism/diagnosis , Thyroid Gland/immunology , Turner Syndrome/immunology , Adolescent , Autoantigens/immunology , Child , Female , Humans , Hypothyroidism/blood , Hypothyroidism/complications , Hypothyroidism/immunology , Iodide Peroxidase/immunology , Iron-Binding Proteins/immunology , Retrospective Studies , Thyroglobulin/immunology , Thyrotropin/blood , Thyroxine/blood , Turner Syndrome/blood , Turner Syndrome/complications
5.
Pediatr Endocrinol Diabetes Metab ; 25(3): 122-126, 2019.
Article in English | MEDLINE | ID: mdl-31769270

ABSTRACT

INTRODUCTION: Polycystic ovary syndrome (PCOS) accounts for 72-84% of adult hyperandrogenism, and in the majority of cases it begins during puberty. The diagnosis based on the Rotterdam criteria seem not to be efficient enough in adolescents. AIM OF THE STUDY: was the analysis of the frequency of PCOS according to Rotterdam criteria in adolescents. MATERIAL AND METHODS: Twenty-six girls with menstrual disorders and/or symptoms of hyperandrogenism two years after menarche were enrolled. We analysed medical history, clinical symptoms, pelvic ultrasound, and testosterone concentration (T). RESULTS: The study group was divided into three subgroups: with isolated cutaneous manifestation (CM) of hyperandrogenism (n = 6), with isolated menstrual disorders (MD; n = 10), and with cutaneous manifestation and menstrual disorders (CMMD; n = 10). We compared total T (cut-off points: > 42 ng/dl and > 55 ng/dl) and polycystic ovarian morphology (PCOM) occurrence. PCOM was detected in 54% of girls, with the highest proportion in the MD group (70%). Using a testosterone cut-off point of > 42 ng/dl, hyperandrogenaemia was confirmed in 81% with a preponderance of the CMMD group (90%). Eleven patients (42%) met all Rotterdam criteria. By more restrict-ed criteria with a testosterone cut-off point of > 55 ng/dl, hyperandrogenaemia was confirmed in 54% of patients, with the highest con-tribution in the CMMD group (70%), and seven patients (27%) met all Rotterdam criteria. Study did not show any correlation between T and ovarian volume (p = 0.695; Rs= 0.08). CONCLUSIONS: In our study 27% of patients suspected of PCOS met all Rotterdam criteria. The co-occurrence of symptoms increases the probability of hyperandrogenaemia.


Subject(s)
Polycystic Ovary Syndrome/diagnosis , Adolescent , Female , Humans , Hyperandrogenism , Menstruation Disturbances , Polycystic Ovary Syndrome/diagnostic imaging , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL